Form 4: Immuneering Corp Executive Harold Brakewood Receives Option Repricing

Harold Eugene Brakewood, Chief Business Officer of Immuneering Corp, had stock options repriced to $3.01 per share, according to a Form 4 filing.

Summary

• Harold Eugene Brakewood, the Chief Business Officer of Immuneering Corp, had his stock options repriced on May 21, 2024.
• The new exercise price is $3.01 per share.
• The repricing was approved by the Issuer's Board of Directors.
• If Brakewood is terminated for cause, resigns (except due to death or disability), or elects to exercise the repriced options before June 30, 2025, the exercise price reverts to the original price.
• 165,000 options were repriced from $9.71 to $3.01, and 60,500 options were repriced from $6.09 to $3.01.
• The options vest over time, subject to continued employment.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects a standard executive compensation adjustment. The impact depends on individual investor perspective.

Positives

• The repricing may incentivize the executive to remain with the company.
• The repricing could make the options more valuable to the executive, aligning their interests with shareholders.

Negatives

• The repricing could be seen negatively by shareholders if the original option prices were significantly higher, as it dilutes the value of existing shares.
• The potential reversion of the exercise price adds complexity to the option terms.

Risks

• If the executive leaves the company before June 30, 2025, and the options revert to the original price, the repricing benefit is lost.
• There is a risk of shareholder dissatisfaction if the repricing is perceived as overly generous to the executive.

Future Outlook

The future value of the options depends on the company's stock performance and the executive's continued employment.

Management Comments

• The Issuer's Board of Directors approved an option repricing.

Industry Context

Option repricing is a common practice to incentivize executives, especially in volatile markets or when a company's stock price has declined.

Comparison to Industry Standards

• Option repricing is a tool used by companies like Immuneering to retain and motivate key executives, similar to practices seen in other biotech firms facing stock volatility.
• Companies such as Amgen, Gilead Sciences, and Biogen also use stock options as part of their executive compensation packages, though the specific terms and conditions vary widely based on company performance and individual circumstances.
• The vesting schedules and conditions attached to these options are generally in line with industry standards, aiming to align executive interests with long-term shareholder value.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the exercise of these options.
• The executive is incentivized to improve company performance to increase the value of the options.

Next Steps

• The executive continues to vest in the options according to the original vesting schedule.
• The company monitors the executive's employment status to ensure compliance with the repricing terms.

Key Dates